Login / Signup

A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma.

Tom Wei-Wu ChenChia-Lang HsuRuey-Long HongJen-Chieh LeeKoping ChangChih-Wei YuSan-Chi ChenJhe-Cyuan GuoMei-Lu ChenMeng-Chi HsuTing-Fang KungAnn-Lii ChengChueh-Chuan Yen
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Lenvatinib plus eribulin has a manageable safety profile and exhibits promising efficacy for treating advanced leiomyosarcoma and liposarcoma.
Keyphrases
  • metastatic breast cancer
  • phase ii
  • randomized controlled trial
  • open label
  • study protocol
  • phase iii